Financial Health Report: Aquestive Therapeutics Inc (AQST)’s Ratios Tell a Tale

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Aquestive Therapeutics Inc (NASDAQ: AQST) closed the day trading at $2.50 down -6.72% from the previous closing price of $2.68. In other words, the price has decreased by -$6.72 from its previous closing price. On the day, 2.21 million shares were traded. AQST stock price reached its highest trading level at $2.65 during the session, while it also had its lowest trading level at $2.45.


For a better understanding of AQST, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.85 and its Current Ratio is at 6.28.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on May 10, 2024, initiated with a Outperform rating and assigned the stock a target price of $8.

On April 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.

On March 28, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.Raymond James initiated its Outperform rating on March 28, 2024, with a $7 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Schobel Alexander Mark sold 50,000 shares for $6.00 per share. The transaction valued at 300,000 led to the insider holds 984,476 shares of the business.

Schobel Alexander Mark sold 25,000 shares of AQST for $129,685 on Mar 08 ’24. The Chief Innovation/Tech Officer now owns 1,040,371 shares after completing the transaction at $5.19 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 243983232 and an Enterprise Value of 166876336. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.42. Its current Enterprise Value per Revenue stands at 3.24 whereas that against EBITDA is -9.169.

Stock Price History:

The Beta on a monthly basis for AQST is 2.79, which has changed by 0.36612022 over the last 52 weeks, in comparison to a change of 0.2586832 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -25.60%, while the 200-Day Moving Average is calculated to be -7.24%.

Shares Statistics:

Over the past 3-months, AQST traded about 2.13M shares per day on average, while over the past 10 days, AQST traded about 1152710 shares per day. A total of 91.04M shares are outstanding, with a floating share count of 79.75M. Insiders hold about 12.40% of the company’s shares, while institutions hold 39.45% stake in the company. Shares short for AQST as of 1715731200 were 6183555 with a Short Ratio of 3.14, compared to 1713139200 on 4008551. Therefore, it implies a Short% of Shares Outstanding of 6183555 and a Short% of Float of 8.140001.

Most Popular